Moneycontrol PRO
HomeNewsOpinionMedPlus’s generic drug push is yielding tangible benefits

MedPlus’s generic drug push is yielding tangible benefits

Traction in private label business has infused positive momentum into MedPlus’s stock

June 02, 2025 / 08:06 IST
Gross margins of the company increased on rising share of private label products in total revenues
Unlock This Article

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

Unlock exclusive discounts